NCT07504055Recruiting
Non-invasive Spinal Cord Stimulation and Blood Pressure Regulation After Spinal Cord Injury
Effectiveness of Transcutaneous Spinal Cord Stimulation on Blood Pressure Regulation in Individuals With Chronic Spinal Cord Injury
Source: ClinicalTrials.gov · Last updated 28 Apr 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if non-invasive spinal cord stimulation intervention improves blood pressure regulation in individuals with chronic spinal cord injury. The main questions it aims to answer are: * Can site specific spinal cord stimulation enhance blood pressure regulation? * Does this stimulation affect enzymes responsible for blood pressure regulation? Researchers will stimulate different sites of spinal cord and compare to see if site-specific stimulation provide blood pressure stability. Participants will have up to six pairs of self-adhesive conductive electrodes placed on the skin over the spinal cord (midline and/or just to the left and right of midline) as cathodes and up to six pairs of self-adhesive electrodes located symmetrically on the skin over the iliac crests, clavicles, shoulders, and/or abdominal muscles (left and right of the umbilicus) as anodes for stimulation of the spinal cord.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 20 Mar 2026
- Start date
- 1 Apr 2026
- Primary completion date
- Feb 2029
- Lead sponsor
- University of Louisville
- Diseases
- High blood pressure
- NCT number
- NCT07504055
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 1 Apr 2026 to the primary completion date, Feb 2029
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Ongoing drug abuse,
Other illness
- Major pulmonary or cardiovascular disease unrelated to SCI,
- Untreated clinically significant depression or psychiatric disorders,
- Malignancy ,
- Acute or chronic obstructive deep vein thrombosis,
- Secondary hypotension unrelated to SCI (anemia, hypervolemia, endocrine and neurological diseases),
- Other major medical illness contraindicated for testing or stimulation.
Lab values
- Class III obesity (BMI \>40) and at least one co-morbidity thereof: a) Type 2 diabetes as defined by ≥6.5% level on two separate glycated hemoglobin (A1C) tests, b) hypertension as defined by consistent blood pressure readings of ≥140/90 mmHg or taking medication for blood pressure,
Other
- Ventilator dependence,
- Painful musculoskeletal dysfunction that might interfere with testing or stimulation,
- Unhealed fracture that might interfere with testing or stimulation,
- Unhealed contracture that might interfere with testing or stimulation,
- Unhealed pressure sore that might interfere with testing or stimulation,
- Major esophageal/gastrointestinal problem,
- Currently pregnant (females of childbearing potential only),
Who the study is looking for
- At least 18 years old,
- Stable medical condition,
- Non-progression SCI (no negative change in the neurological level and motor-completeness assess during screening when compared to the neurological status assessed at 6-month period after injury or at least 6 months prior to the screening),
- Motor-complete SCI according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade "A," "B," or "C" above T1 spinal level according to the ASIA International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) Neurological Level of Injury (NLI),
- Sustained SCI at least 12 months prior to entering the study,
- Evidence of symptomatic hypotension as determined by a total score \>0 on the Orthostatic Hypotension Symptom Assessment (OSHA),
- Normal renal function as defined by eGFR \> 59 ml/min/1.73, creatinine value within the range of 0.6-1.2 mg/dl, and BUN values within the range of 7-18 mg/dl,
- Competent to give informed consent for the research protocol,
- Able to understand instructions.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Frazier Rehabilitation and Neuroscience Institute Coordinator of this site? Confirm its status | Louisville | United States | Not yet recruiting |
| Frazier Rehabilitation Institute Coordinator of this site? Confirm its status | Louisville | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.